Special Issue "Influenza Virus and Vaccine Development"
A special issue of Vaccines (ISSN 2076-393X). This special issue belongs to the section "Vaccines against (re)emerging and Tropical Infections Diseases".
Deadline for manuscript submissions: closed (31 December 2020) | Viewed by 12833
Interests: influenza viruses; vaccines; vaccination; serology; correlates of protection.
Interests: influenza pathogenesis; animal model; virus-host interaction; infection and immunity; vaccinology; antigenicity; humoral immunity; cellular immunity
Influenza is a significant public health concern. Conventional vaccines (split, subviron or recombinant vaccines) mainly target viral hemagglutinin (HA) on the surface of viral particles and elicit neutralizing antibodies to prevent influenza infections. However, influenza viruses undergo frequent antigenic drift and/or antigenic shift that often compromise influenza vaccine performance or result in seasons with vaccine mismatch and poor protection.
We are calling for manuscripts detailing the mechanisms of influenza virus replication and pathogenesis and describing how this information facilitates novel vaccine development. We particularly encourage submission of manuscripts that are not limited to HA but address other viral proteins (e.g., neuraminidase, matrix protein, polymerases) and/or different vaccine formats (e.g., DNA vaccine, viral-like particle). We sincerely hope this Special Issue serves as a platform for the exchange of the latest developments in the field of influenza virus and vaccines.
Dr. Ewan Plant
Dr. Hang Xie
Manuscript Submission Information
Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.
Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Vaccines is an international peer-reviewed open access monthly journal published by MDPI.
Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2200 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.
- influenza viruses
- correlates of protection
- influenza pathogenesis
- animal models
- virus–host interaction
- infection and immunity
- humoral immunity
- cellular immunity